Loading...
•
Jun 30, 2025
Alvotech Q2 2025 Earnings Report
Alvotech posted a strong second quarter with $173.2 million in total revenue and $32 million in net income, continuing its positive cash flow momentum.
Key Takeaways
Alvotech delivered robust Q2 2025 results, highlighted by growth across biosimilar products and global expansion. The company generated $173.2 million in revenue and $32 million in net income. Product launches and cost management contributed to improved profitability and cash performance.
Total revenue for Q2 reached $173.2 million, driven by product and license income.
Net income totaled $32 million, following a strong Q1 performance.
EPS came in at $0.11 with adjusted EPS at $0.14.
Q2 marked the second consecutive quarter of positive operating cash flow.
Revenue by Segment
Forward Guidance
Alvotech maintained its guidance for FY 2025, projecting $600–700 million in revenue and $200–280 million in adjusted EBITDA, driven by continued product rollout and global expansion.
Positive Outlook
- Full-year revenue guidance reaffirmed at $600–700 million.
- Adjusted EBITDA expected to reach $200–280 million.
- Strong demand for biosimilars in key markets.
- New commercial partnerships established in Q2.
- Continued improvement in cash flow from operations.
Challenges Ahead
- License revenue declined YoY due to milestone timing.
- Exchange rate fluctuations impacted income.
- Q2 operating margin was lower than Q1.
- R&D expenses increased due to clinical program investments.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...